COVID-19 survivors who received their first dose of the COVID-19 vaccine are producing immune responses that may render a second shot unnecessary, possibly releasing a limited vaccine supply for more people, many. New research papers suggest.

Research, while preliminary, found that previously infected people produced protection against the disease at a dramatically higher level after the current two-shot first shot, and at a dramatically higher level when compared with those vaccinated. Was done, but was not ill.

Viviana Simon, a professor of microbiology at New York’s Econ School of Medicine in Mount Sinai and a writer on a study, said, “Everyone should get vaccinated. Not everyone needs two shots.” “Until we can give the vaccine to everyone who wants it, I think it’s an important consideration.”

SANOFI PRODUCTION JOHNSON & JOHNSON COVID-19 VACCINES

The research, which is posted on a preprint server but not peer reviewed or published in a scientific journal, comes as other findings in a two-injected diet to healthy members of the general population Highlight immune benefits after the first injection. On Friday, researchers in Israel reported a shot of the vaccine from Pfizer Inc. and Bioentech is 85% effective at preventing symptomatic disease 15 to 28 days after being administered to SE.

Late-stage clinical trials of two-dose vaccines by Pfizer and BioNotech, as well as Modern Inc., have shown their shots to be safe and highly protective against COVID-19 when the two doses were given at different weeks. However, Pfizer’s trial excluded individuals with symptomatic COVID-19, and Modern excluded those with previously known infections, prompting researchers to see how the immune system reacted in previously ill people Does.

GSK, SANOFI START NEW COVID-19 Vaccine Study Site

A spokesman said that Pfizer did not have data regarding the single-dose approach in COVID-19 survivors. A spokesman said that Modern Preprint is aware of the data but is not studying the issue.

Just one dose means that health officials can reduce the extra dose for more people and speed up the reach of vaccination, which vaccine experts and health officials say are important in the transmission of new forms of the virus . Limited initial supplies have contributed to the blunt rollout of the vaccine and forced governments to favor high-risk individuals ahead of others.

Find out the full story Wall Street Journal.